Tectonic Therapeutic Inc (TECX)
Tectonic Therapeutic, Inc. is a biotechnology company listed on the NASDAQ under the ticker TECX. The company focuses on discovering and developing therapeutic proteins and antibodies designed to modulate the activity of G protein coupled receptors, or GPCRs. Its GEODe technology platform is intended to support the identification and development of GPCR-targeted biologic medicines. Tectonic’s lead program is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, a GPCR target associated with the hormone relaxin. The pipeline also includes TX2100 for hereditary hemorrhagic telangiectasia, a GPCR modulator bispecific for fibrosis, and additional GPCR modulator candidates. The company is headquartered in Watertown, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TECX
|
$27.07
|
-16.5% Downside
|
Fair
|
$78.44
|
142.1% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 19, 2026
|
-7.4x
|
2.7x
|
—
|
605.1 M
|
383.9 M
|
0.8%
|
59.5%
|
20.9
|
—
|
78.6%
|
